Antiepileptic drug review: part 2.
Winkler
S R
SR
University of Illinois at Chicago, College of Pharmacy, 60612-7230, USA.
Luer
M S
MS
D000085:Acetates / Q000627:therapeutic use; D000588:Amines; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001682:Biological Availability; D003509:Cyclohexanecarboxylic Acids; D004347:Drug Interactions; D000078328:Felbamate; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077206:Gabapentin; D006207:Half-Life; D006801:Humans; D000077213:Lamotrigine; D048448:Phenylcarbamates; D010672:Phenytoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011409:Propylene Glycols / Q000627:therapeutic use; D000077236:Topiramate; D014227:Triazines / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D048448:Phenylcarbamates; D011409:Propylene Glycols; D014227:Triazines; D000077236:Topiramate; D005632:Fructose; D005680:gamma-Aminobutyric Acid; D010672:Phenytoin; D000077206:Gabapentin; C043114:fosphenytoin; D000077213:Lamotrigine; D000078328:Felbamate